Major Response to Imatinib Mesylate in <i>KIT</i>-Mutated Melanoma-Reference-Cited by-同舟云学术

Major Response to Imatinib Mesylate in KIT-Mutated Melanoma

Published:2008-04-20 Issue:12 Volume:26 Page:2046-2051
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Hodi F. Stephen¹,Friedlander Philip¹,Corless Christopher L.²,Heinrich Michael C.²,Mac Rae Suzanne³,Kruse Andrea³,Jagannathan Jyothi⁴,Van den Abbeele Annick D.⁴,Velazquez Elsa F.⁵,Demetri George D.⁶,Fisher David E.⁷

Affiliation:

1. The Melanoma Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

2. Division of Hematology and Oncology, Oregon Health and Science University, Portland, OR

3. The Melanoma Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

4. Department of Radiology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

5. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

6. Department of Medical Oncology, Ludwig Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

7. The Melanoma Program, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2007.14.0707

Reference20 articles.

1. KIT Mutations Are Common in Incidental Gastrointestinal Stromal Tumors One Centimeter or Less in Size

2. Primary mucosal melanoma

3. Barnhill RL: Textbook of Dermatopathology (ed 2). New York, NY, McGraw-Hill Health Pub Division, 2004

4. Somatic Activation of KIT in Distinct Subtypes of Melanoma

5. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

Cited by 391 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) against Kit-mutant melanoma;Bioactive Materials;2025-04

2. Primary Anorectal Mucosal Melanoma: A Unique Presentation of Mucosal Melanomas;Cureus;2024-09-24

3. Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting;Melanoma Research;2024-08-30

4. Anticancer Effects of 4-Hexylresorcinol;Biomedical Application of 4-Hexylresorcinol;2024

5. Acral melanoma: new insights into the immune and genomic landscape;Neoplasia;2023-12